AustriaAustria

Biopatent Directive implemented

10.07.2005

Vienna - With a five-years' delay Austria's National Council has implemented the bio-
patent directive of the European Commission into national law. Since the set of rules is highly disputed in Austria only the governing ÖVP/FPÖ coalition agreed. Especially the possibility of patents on DNA sequences is met with criticism. Supporters again stressed the fact that now finally substantial grey zones are eliminated concerning the patenting of biological materials - particularly of genes.
An opposition spokesman justified the refusal of its parliamentary group with the fact that now “patenting of lives and genes” becomes possible. Other countries have demonstrated that the EU directive could have been implemented differently. In Germany it is almost impossible to patent a gene on the grounds of only one of possibly thousands functions, and human germ cells are not patentable at all. In contrast the interpretation in Austria is more liberal and to a large extent the unmodified EU text. According to the law, biological material isolated or made with the help of a technical procedure from its natural environment can be patented even if it was already present in nature. Sequences of genes, even if the structure of this component is identical to the structure of a natural component are also patentable.

AustriaAustria

09.03.2012

Breast cancer patients who receive radiation therapy often suffer from inflammation linked to the treatment. Austrian Apeiron Biologics AG is now developing a topical superoxide dismutase treatment (APN201) to try to help these...

AustriaAustria

06.03.2012

The Paracelsus Private Medical University (PMU) in Salzburg is to build a new research center for spinal cord injuries. The €70m construction tab will be picked up by Dietrich Mateschitz, the owner of Red Bull. Other partners in...

AustriaAustria

16.12.2011

Vienna – Two big investors have poured €25m into Austrian vaccine specialist Affiris AG. Venture fund Santo VC – the investment vehicle of German biotech investors Thomas and Andreas Strüngmann – donated €20m, while the German...

AustriaAustria

08.11.2011

Vienna – In Affiris they trust – as a proof of their faith, two big investors poured €25 million into the Austrian developer of a possible Alzheimer drug. Venture fonds Santo VC, the investment vehicle of the German billionaires...

AustriaAustria

17.08.2011

Innsbruck – Austrian specialist for so-called ugimeres, Ugichem GmbH, has landed fresh funding. Along with V+ GmbH and the Austrian Research Promotion Agency, Swiss private investors invested about EUR2m to develop the first...

AustriaAustria

12.08.2011

Innsbruck – An Austrian physician has been fined EUR4,500 in a case involving a controversial stem cell therapy for incontinence. In early August, an Innsbruck Regional Court adjudged Hannes Strasser, who developed the method, at...

AustriaAustria

11.06.2011

Vienna – Nabriva Therapeutics AG, an Austrian specialist for the development of novel antibiotics, has achieved proof-of-concept for its first product in a clinical Phase II study. Called BC-3781, the compound is used to treat...

AustriaAustria

11.06.2011

Vienna – Nabriva Therapeutics AG, an Austrian specialist for the development of novel antibiotics, has achieved proof-of-concept for its first product in a clinical Phase II study. Called BC-3781, the compound is used to treat...

AustriaAustria

28.04.2011

Vienna - f-star, an antibody specialist, today announced the closing of aEUR 15 Million financing. The investment was led by SR One, the corporate venture capital arm of GlaxoSmithKline. All of f-star’s existing investors, Atlas...

Displaying results 1 to 10 out of 116

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-austria/article/biopatent-directive-implemented.html

Product of the week

Products

Events

All Events

Current issue

All issues